Since only few preneoplastic lesions progress to HCC following CMD withdrawal [30], we investigated whether Nrf2 activation could represent a growth advantage for the progression of preneoplastic lesions to malignancy after CMD withdrawal (Figure 1A). This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.